Thermo Fisher Scientific’s $9B acquisition of Clario Holdings, Inc.

Abstract

This analysis examines the completed acquisition of Clario Holdings, Inc. (“Clario”) by Thermo Fisher Scientific Inc. (“Thermo Fisher”), announced on 29.10. 2025. After a brief overview of the deal itself and the companies involved, this piece will address the key legal considerations and the potential impact of the transaction—a deal that strengthens Thermo Fisher’s leading position as a global provider of laboratory and research solutions and Contract Research Organization (“CRO”) services, and extends its activities into later stages of the drug development and approval process with a view to streamlining the submission pathways to the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”), and other global regulators by integrating Clario’s regulatory-grade cardiac safety, medical imaging, and eCOA data platforms into PPD’s clinical trial management infrastructure. The deal was closed on 24.03.2026.

Deal Overview

• Type of transaction: Acquisition

• Parties involved: Thermo Fisher Scientific Inc. (acquirer) and Clario Holdings, Inc. (target); sellers: Nordic Capital, Astorg, Cinven, and Novo Holdings

• Transaction size: $8.875 B + depending on performance:  earnout and other payments

• Transaction structure: Cash

• Closing: 24.03.2026

Thermo Fisher’s acquisition of Clario is strategically motivated by the opportunity to integrate Clario’s unique, complete endpoint data platform into its existing CRO infrastructure through PPD. As set out in the Target Overview, Clario is the only provider in the market capable of delivering the full spectrum of clinical trial endpoint data services—cardiac safety (centralized ECG and Holter monitoring), electronic Patient-Reported Outcomes (“ePRO”), electronic Clinical Outcome Assessments (“eCOA”), respiratory efficacy, and medical imaging—from a single integrated platform. This breadth, which rivals such as IQVIA, ICON, and Syneos Health cannot match in-house, is precisely what PPD lacked and what Thermo Fisher has now acquired. The combination allows Thermo Fisher to offer pharmaceutical and biotechnology clients a single-source, fully integrated provider across site selection, patient recruitment, and endpoint data collection across all modalities, as well as regulatory submission support—a proposition no competitor can replicate without analogous acquisitions. The all-cash consideration of $8.875 billion, supplemented by contingent earnout provisions, was announced on 29.10.2025. The transaction closed on 24.03.2026. Wilmer Cutler Pickering Hale and Dorr LLP served as Thermo Fisher’s principal deal counsel while Axinn, Veltrop & Harkrider LLP and Freshfields LLP served as regulatory counsel. Jefferies LLC acted as lead financial advisor to Clario. Evercore acted as co-lead financial advisor to Clario. Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, UBS Investment Bank, Goldman Sachs and BofA Securities, Inc. acted as financial advisors and Latham & Watkins LLP as legal counsel to Clario. 

Company Overview: Acquirer

• Year of Foundation: Established through 2006 merger of Thermo Electron Corporation (1956) & Fisher Scientific (1902)

• Founders: George N. Hatsopoulos, Peter M. Nomikos (Founders of Thermo Electron Corporation) and Chester G. Fisher (Founder of Fisher Scientific)

• CEO (at time of acquisition): Marc N. Casper

• Market Valuation: $ 191.08B as of 03.03. 2026

Thermo Fisher Scientific Inc. is one of the world’s foremost life sciences companies, whose mission is “to enable our customers to make the world healthier, cleaner and safer”, serving pharmaceutical and biotechnology clients, academic and government research institutions, and healthcare and diagnostics providers. The company took its current form through the 2006 merger of Thermo Electron Corporation—itself founded in 1956 by George Hatsopoulos as a scientific instrumentation business spun out of MIT—and Fisher Scientific International, whose origins in chemical and laboratory supply date to 1902. The combined entity has pursued an aggressive acquisition-led growth strategy ever since. Landmark deals include the acquisition of Life Technologies Corporation in 2014 for approximately $13.6 billion, which established Thermo Fisher’s dominance in molecular biology tools, next-generation sequencing reagents, and genomics consumables, and the acquisition of Patheon NV in 2017 for approximately $7.2 billion, extending the company into pharmaceutical contract manufacturing and drug development services. Most significant for the strategic context of the Clario transaction was Thermo Fisher’s 2021 acquisition of PPD, Inc.—one of the world’s largest CROs—for approximately $17.4 billion. That deal established Thermo Fisher as a leading provider of Phase I through Phase IV clinical trial management services globally and formed the platform onto which Clario’s endpoint technology capabilities are now intended to be integrated. Thermo Fisher’s PPD division competes directly with IQVIA Holdings, ICON Plc, and Syneos Health—the three other major full-service CROs which are also direct competitors of Clario—all of which lack a comparably integrated proprietary endpoint data platform. Thermo Fisher itself navigated a significant post-pandemic revenue contraction, with annual revenues declining from approximately $44.9 billion in 2022 to $42.9 billion in 2023 as COVID-19 testing and vaccine manufacturing revenues normalised; the Clario acquisition is in part a strategic response, as the vertical integration of proprietary endpoint technology creates a differentiated, higher-margin offering that commodity CRO competitors cannot easily replicate.

Company Overview: Target

• Year of Foundation: 1972 (as Cardio Data Systems; rebranded as Clario in November 2021 following the merger of ERT and Bioclinica)

• CEO (at time of acquisition): Chris Fikry, M.D.

• Deal Consideration (up to): $9.4 billion ($8.875 billion cash at close, plus $125 million deferred January 2027 and up to $400 million in performance-based earnouts for 2026–2027)

Clario resulted from the November 2021 merger of eResearchTechnology, Inc. (“ERT”) and Bioclinica, Inc., a combination that valued the merged entity at approximately $6 billion. ERT was established in 1972 as Cardio Data Systems and Bioclinica’s predecessor Bio-Technologies was incorporated in 1990. Cardio Data Systems went public in 1996 as Premier Research Worldwide and then changed its name in 2000 into eResearch Technology under which the company continued to exist until Clario was formed. In 2012 ERT was taken private by San Francisco-based Genstar Capital LLC in a transaction valued at approximately $400 million. In 2016 ERT was sold to Nordic Capital, with Novo Holdings as minority investor, for approximately $1.8 billion. In 2019 Astorg joined as a co-investor while Nordic Capital and Novo Holdings reinvested, valuing ERT at approximately $4.4 billion. Bioclinica had itself followed a parallel private equity trajectory: it was taken private in 2013 by JLL Partners in a transaction valued at approximately $123 million, and subsequently merged in 2014 with CCBR-SYNARC, a clinical imaging specialist then owned by Water Street Healthcare Partners, to broaden its service offering. In 2016, Cinven acquired Bioclinica from Water Street Healthcare Partners and JLL Partners in a transaction valued at approximately $1.4 billion, holding the business through its continued growth as a standalone PE-backed platform until the 2021 merger with ERT formed Clario.

While Bioclinica had positioned itself as a medical imaging provider, Cardio Data Systems as predecessor of ERT dealt with the analysis of ambulatory (Holter) electrocardiograms (“ECG”). A Holter ECG is a wearable monitoring device that continuously tracks the heart’s electrical activity, typically over 24 to 48 hours, to detect intermittent arrhythmias, palpitations, and other cardiovascular issues that tend not to appear on a standard short-term ECG. Their first Holter study was concluded in 1975 and by the end of the year Cardio Data Systems became the largest U.S. research provider for the evaluation of cardiovascular drugs for approval by the U.S. Food and Drug Administration (“FDA”). This dominant market position was primarily built on the regulatory credibility gained by analysing 4,500 Holter readings for a Beta Blocker Heart Attack trial conducted by the National Institutes of Health, establishing a level of FDA trust no contemporary competitor could match. In the 1980s and 1990s, principal rivals included BioMedical Systems (founded 1975), Covance Cardiac Safety Services, and Quintiles ECG Services—each of which either entered the market later, lacked an international footprint, or relied on manual analogue processing. Cardio Data Systems expanded its first-mover advantage by pioneering the computerised analysis of 12-lead ECGs from 1990, materially accelerating FDA drug approval submissions, and by expanding internationally to the United Kingdom in 1987 when rivals remained domestically focused. A further pioneering step was the development of electronic patient questionnaire forms and platforms, an early form of what would become electronic Patient-Reported Outcomes (“ePRO”): the digital capture of a patient’s own assessment of their symptoms, functioning, and quality of life during a clinical trial. ERT formally launched a dedicated ePRO product line in 2007, and subsequently acquired invivodata in 2012 and PHT Corporation in 2015 to consolidate its position as a leading ePRO provider. ePRO data, alongside clinician-reported and observer-reported outcomes, forms part of the broader category of electronic Clinical Outcome Assessments (“eCOA”)—the full suite of digitally collected evidence that regulators require to evaluate how a drug affects how patients feel and function. Bioclinica, for its part, developed deep expertise in medical imaging as a clinical endpoint—the central, standardised reading of MRI, CT, and PET scans to measure tumour response, disease progression, or neurological change across multi-site trials. The November 2021 merger of ERT and Bioclinica into Clario was therefore strategically transformative because it created the only provider capable of delivering every major endpoint data category—cardiac safety, ePRO and eCOA, respiratory efficacy, and medical imaging—from a single integrated platform. No full-service CRO, including IQVIA, ICON, Syneos Health, or LabCorp’s Covance division, offers comparable in-house breadth; all rely to varying degrees on third-party specialist vendors for these services. This structural position as the sole complete endpoint solutions provider is the foundation of Clario’s commercial moat and, as discussed below, the central strategic rationale for Thermo Fisher’s acquisition. This breadth also enabled Clario’s platform to support approximately 70% of FDA drug approvals over the past decade, according to company-stated figures. Consistent with this legacy, Clario’s mission is “to transform lives by unlocking better evidence”.

As a consequence of successive private equity ownership cycles, by 2024 Clario carried a leverage burden of nearly $4 billion in private debt. In June 2024 its shareholders confidentially filed for an initial public offering (“IPO”), targeting a valuation above $10 billion and engaging JPMorgan, Morgan Stanley, Jefferies, and UBS as underwriters. That listing was ultimately abandoned as sustained weakness in CRO and healthcare technology public market valuations—driven by falling biotech venture funding and rising interest rates—made a standalone listing commercially unattractive. With Nordic Capital, Astorg, Cinven, and Novo Holdings each approaching the end of their typical holding horizons, a trade sale to a well-capitalised strategic acquirer became the preferred exit, making the resulting Thermo Fisher transaction the largest full healthcare private equity exit globally in 2025.

Legal Contentions

Having presented the commercial and strategic background to Thermo Fisher’s acquisition of Clario, the key legal contentions are addressed below across three areas: corporate and applicable law; antitrust and regulatory oversight; and data privacy and clinical regulatory compliance.

Corporate Structure and Applicable Law

Thermo Fisher Scientific Inc. is incorporated in Delaware and listed on the New York Stock Exchange (NYSE: TMO). Clario Holdings, Inc. is a privately held company operating under US law. As both the acquirer and target are US-domiciled entities, the transaction is primarily governed by Delaware corporate law—specifically the Delaware General Corporation Law (DGCL)—which provides the statutory framework for the merger or acquisition structure. Because the consideration is entirely cash and no new registered securities are being issued, there is no obligation to register transaction securities under the Securities Act of 1933. However, Thermo Fisher, as a public company, must comply with its ongoing disclosure obligations under the Securities Exchange Act of 1934, including material event disclosures on Form 8-K following the announcement and at closing. Thermo Fisher’s compliance with NYSE Marketplace Rules and SEC reporting requirements will also govern public-facing disclosure obligations throughout the deal period.

Internationally, Clario maintains significant operations in Europe and other jurisdictions, including clinical data management facilities that operate under EU and national regulatory frameworks. The transfer of Clario’s European subsidiaries will engage local corporate law requirements across the relevant member states, which may include change-of-control notifications to local authorities and the renegotiation or novation of local employment agreements in a manner consistent with applicable labor law, including the EU’s Transfer of Undertakings framework or its national equivalents.

Regulatory Risk and Antitrust

Given Thermo Fisher’s revenues exceeding $42 billion annually, the transaction comfortably surpassed the notification thresholds of the Hart–Scott–Rodino Antitrust Improvements Act of 1976 (“HSR Act”), 15 U.S.C. § 18a, requiring pre-merger notification to the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice (“DOJ”). Those agencies were empowered to request further information, extend the initial waiting period, or seek injunctive relief if the transaction was found likely to substantially lessen competition contrary to Section 7 of the Clayton Act of 1914 (15 U.S.C. § 18). The key competition law question centred on whether vertical integration of Clario’s endpoint platforms into PPD would create barriers for pharmaceutical sponsors wishing to use PPD for trial management alongside a competing endpoint provider, or for rival CROs wishing to access Clario’s services. The deal received US antitrust clearance without conditions.

In Europe, the EU Merger Regulation [Council Regulation (EC) No 139/2004] is likely applicable. Article 1(2) of that Regulation assigns jurisdiction to the European Commission where the combined worldwide turnover of the undertakings exceeds €5 billion and each of the undertakings has EU-wide turnover exceeding €250 million. Thermo Fisher’s global revenues substantially exceeded the €5 billion threshold, and Clario’s European clinical operations were sufficient to cross the €250 million EU-wide individual threshold, triggering mandatory pre-closing notification to the European Commission under the one-stop-shop principle and displacing national competition agencies. On 20.03.2026, the European Commission granted unconditional clearance (Case M.12264), concluding that the transaction would not raise competition concerns given its limited impact on competition in the relevant markets, and specifically finding that the merged entity would not have the ability to engage in any foreclosure strategy against rival CROs. The deal closed on 24.03.2026, four days after clearance.

Data Privacy and Clinical Regulatory Compliance

Clario’s operations are fundamentally data-intensive: it collects, processes, and transmits highly sensitive patient-level clinical trial data, including continuous ECG recordings, medical imaging studies, and patient-reported outcome data, across global clinical trial networks. The transfer of this data infrastructure to Thermo Fisher implicates multiple data privacy and regulatory compliance frameworks.

In the United States, clinical trial data involving human subjects is regulated under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations under 45 C.F.R. Parts 160 and 164, which impose strict requirements on the use, disclosure, and safeguarding of Protected Health Information (PHI). The acquisition will require a comprehensive review of Clario’s existing Business Associate Agreements (BAAs) with pharmaceutical sponsors and clinical sites, and the appropriate novation or replacement of those agreements to reflect the change of control. Additionally, Clario’s electronic systems for capturing trial data must comply with the FDA’s 21 CFR Part 11 regulations governing electronic records and electronic signatures, which may require re-validation or re-qualification of key systems following integration. Any clinical laboratory services provided by Clario will also need to address the Clinical Laboratory Improvement Amendments (CLIA) and associated state-level requirements in connection with the ownership transfer.

In Europe, the processing and transfer of clinical trial data is subject to the General Data Protection Regulation (EU) 2016/679 (GDPR), under which health data is classified as a “special category” of personal data under Article 9, attracting the highest level of protection and requiring explicit legal bases for processing. Clario’s integration into Thermo Fisher will require Data Protection Impact Assessments (DPIAs) in jurisdictions where Clario processes EU data, and may require advance consultation with national data protection authorities (DPAs). The cross-border transfer of EU patient data to Thermo Fisher’s US data infrastructure continues to be governed by the EU–US Data Privacy Framework, adopted in 2023 following the Schrems II judgment. While the Framework currently provides a mechanism for compliant transatlantic data transfers, it remains subject to ongoing legal challenge in European courts, and Thermo Fisher should ensure that contractual and technical safeguards—such as Standard Contractual Clauses—are maintained in parallel.

Industry Impact

The acquisition represents a further and significant episode of consolidation in the clinical research sector, which has undergone substantial structural transformation over the past decade. Clario occupies a specialized but pivotal niche: it is not a full-service CRO in the traditional sense but rather a clinical trial endpoint solutions provider, supplying the regulatory-grade measurement and data collection infrastructure upon which pharmaceutical companies rely to demonstrate the safety and efficacy of candidate drugs to the FDA, the European Medicines Agency (“EMA”), and other regulators. Its services—spanning cardiac safety monitoring, medical imaging endpoint assessment, and electronic patient-reported outcomes—are woven into hundreds of active clinical trials globally. The integration of this platform into Thermo Fisher’s PPD infrastructure creates a vertically integrated clinical research offering of a scale not previously seen in the market.

For pharmaceutical and biotechnology clients, the deal creates a more powerful but potentially less diversified vendor landscape. Where previously a sponsor might engage PPD for trial management and Clario or a competitor for endpoint services, post-merger Thermo Fisher will be positioned to bundle these offerings. Competitors in the endpoint solutions space may face heightened competitive pressure. Larger CRO peers, including IQVIA Holdings, ICON Plc, Syneos Health, and LabCorp’s Covance division, may be prompted to pursue analogous acquisitions of specialist endpoint technology companies to maintain competitive parity. The deal thus has the character of a sector-catalysing event, likely to accelerate further consolidation in adjacent clinical research technology markets.

Following closing on 24.03.2026, Clario will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment, which generated $23.1 billion in sales in 2024. Financially, Thermo Fisher has guided that the acquisition is immediately accretive to its adjusted operating margin and will add approximately $0.45 of adjusted earnings per share in the first full year following close. The Clario business is expected to grow at a high single-digit rate annually, and Thermo Fisher projects approximately $175 million in adjusted operating income from synergies by year five, driven primarily by cross-selling Clario’s endpoint data solutions to PPD’s existing pharmaceutical client base.

From a governance perspective, Thermo Fisher has not publicly disclosed the post-close leadership structure for the integrated Clario business; the closing press release names no continuing Clario executives, making the retention of specialist management an open integration question and a key determinant of whether the platform’s regulatory credibility is preserved under new ownership.

House View

Now that the acquisition has closed, the strategic logic is being tested in execution. The combination of Clario’s endpoint technology platform with PPD’s clinical trial management infrastructure creates a vertically integrated clinical research offering that spans from trial design and site management through to regulatory-grade endpoint data collection and submission support. This level of integration is difficult for competitors to replicate quickly and materially enhances the stickiness of Thermo Fisher’s client relationships. Thermo Fisher has not publicly confirmed any post-close leadership arrangements for the Clario business, and the integration of specialist management teams remains an open and material question.

The European Commission granted unconditional clearance on 20.03.2026, finding no competition concerns and concluding that the merged entity lacks the ability to foreclose rival CROs. This removes what had been the principal regulatory risk. Data privacy compliance and the re-validation of Clario’s 21 CFR Part 11-regulated systems now represent the most immediate ongoing operational legal risk, as any disruption to the integrity of Clario’s regulatory-grade data pipelines could materially affect active clinical trials and expose Thermo Fisher to regulatory and contractual liability.

Beyond regulatory approval, the success of the transaction will hinge substantially on talent retention. Clario’s regulatory credibility rests on the quality of its specialist scientific and clinical staff—cardiologists, biostatisticians, and imaging scientists who provide the expert judgment on which FDA and EMA review panels rely. The risk of key talent departures following deal close, particularly if integration timelines are aggressive or if Clario’s specialist culture is perceived as incompatible with Thermo Fisher’s large corporate environment, is a material concern. The deal is also likely to catalyse further consolidation among CRO competitors. Peers including ICON Plc and Syneos Health may seek analogous acquisitions of remaining independent endpoint technology providers to maintain competitive parity, accelerating the structural transformation of the clinical research industry from a labor services model toward a data-driven, technology-integrated model.

Conclusion

Thermo Fisher’s $8.875 billion acquisition of Clario Holdings, closed on 24.03.2026, represents a defining move in the ongoing consolidation of the global clinical research sector. By combining Clario’s specialised endpoint technology platform—which, according to the company, supported approximately 70% of FDA drug approvals over the past decade—with PPD’s established CRO infrastructure, Thermo Fisher has extended its integrated life sciences offering into the critical domain of clinical trial data collection and regulatory submission. The transaction is legally and commercially coherent, structured as an all-cash deal that avoids the complexity of a share exchange and reflects confidence in Clario’s value as a standalone specialty platform. Key legal considerations—including antitrust clearance under the HSR Act and the EU Merger Regulation (granted unconditionally by the European Commission on 20.03.2026), data privacy compliance under HIPAA and GDPR, and clinical regulatory transfer requirements under 21 CFR Part 11—were substantial but manageable, and did not ultimately prevent closing. The deal has not been without criticism: some analysts have questioned whether Thermo Fisher overpaid at a valuation implying approximately seven times Clario’s projected $1.25 billion 2025 revenue, while others have raised concerns that bundling endpoint services with PPD’s CRO platform may constrain smaller pharmaceutical and biotech sponsors’ ability to use independent endpoint providers, and could over time exert upward pressure on the cost of drug development. The ultimate determinant of whether this acquisition creates enduring value will not be regulatory approval, but rather Thermo Fisher’s capacity to integrate Clario’s specialist scientific talent and proprietary platforms without compromising the regulatory credibility on which Clario’s competitive position depends.

References

Applied Clinical Trials Online (2005). Finding the Right Core ECG Laboratory. [online]. Available at: https://www.appliedclinicaltrialsonline.com/view/finding-right-core-ecg-laboratory [accessed 18 March 2026].

Applied Clinical Trials Online (2015). ERT’s Acquisition of PHT. [online]. Available at: https://www.appliedclinicaltrialsonline.com/view/erts-acquisition-pht [accessed 20.03.2026].

Applied Clinical Trials Online (2016). Bioclinica Enters Agreement to be Acquired by Cinven. [online]. Available at: https://www.appliedclinicaltrialsonline.com/view/bioclinica-enters-agreement-be-acquired-cinven [accessed 25.03.2026].

BioSpace (2007). eResearchTechnology, Inc. Enters Electronic Patient Reported Outcomes (ePRO) Business. [online]. Available at: https://www.biospace.com/eresearchtechnology-inc-enters-electronic-patient-reported-outcomes-epro-business [accessed 20.03.2026].

Clario (2021). ERT and Bioclinica Become Clario. [online]. Available at: https://clario.com/about/newsroom/ert-and-bioclinica-become-clario/ [accessed 20.03.2026].

Council Regulation (EC) No 139/2004 of 20 January 2004 on the control of concentrations between undertakings (the EC Merger Regulation) [2004] OJ L24/1.

European Commission (2023). EU–US Data Privacy Framework. [online]. Available at: https://commission.europa.eu/law/law-topic/data-protection/international-dimension-data-protection/eu-us-data-transfers_en [accessed 20.03.2026].

European Commission (2026). Case M.12264 – Thermo Fisher Scientific / Clario Holdings: Merger Clearance Decision. [online]. Available at: https://competition-cases.ec.europa.eu/cases/M.12264 [accessed 25 March 2026].

Fierce Biotech (2012). Genstar acquires eResearch for $400 mln. [online]. Available at: https://www.fiercebiotech.com/cro/genstar-acquires-eresearch-for-400-mln [accessed 15 March 2026].

Fierce Biotech (2012). ERT scoops up Invivodata for ePRO clinical trials tech. [online]. Available at: https://www.fiercebiotech.com/r-d/ert-scoops-up-invivodata-for-epro-clinical-trials-tech [accessed 20.03.2026].

Fisher Scientific (2022). The Fisher Scientific Brand Turns 120. Lab Reporter. [online]. Available at: https://www.fishersci.de/de/en/lab-reporter/2022/issue-4/the-fisher-scientific-brand-turns-120.html [accessed 15 March 2026].

Hart–Scott–Rodino Antitrust Improvements Act of 1976, 15 U.S.C. § 18a.

Health Insurance Portability and Accountability Act of 1996, Pub. L. 104–191, 110 Stat. 1936.

Latham & Watkins LLP (2022). Latham & Watkins Advises Astorg, Nordic Capital, and Portfolio Company Clario on Divestiture of Clario’s Drug Safety Solutions. [online]. Available at: https://www.lw.com/en/news/latham-watkins-advises-astorg-nordic-capital-portfolio-company-clario-divestiture-clario-drug [accessed 15 March 2026].

MIT News (2018). George Hatsopoulos, senior lecturer emeritus in mechanical engineering and Thermo Electron founder, dies at 90. [online]. Available at: https://news.mit.edu/2018/george-hatsopoulos-senior-lecturer-emeritus-mechanical-engineering-thermo-electron-founder-dies-0921 [accessed 15 March 2026].

Nordic Capital and Astorg (2025). Press Release: Nordic Capital and Astorg Announce Agreement to Sell Clario to Thermo Fisher Scientific. [online]. Available at: https://www.nordiccapital.com/news-views/press-releases/nordic-capital-and-astorg-announce-agreement-to-sell-clario-to-thermo-fisher-scientific/ [accessed 15 March 2026].

Princeton Alumni Weekly (n.d.). Memorial: Peter Nomikos ’53. [online]. Available at: https://paw.princeton.edu/memorial/peter-nomikos-53 [accessed 15 March 2026].

PR Newswire (2012). ERT Acquires invivodata to Establish the Industry’s Most Experienced Provider of Clinical Outcome Assessment Solutions. [online]. Available at: https://www.prnewswire.com/news-releases/ert-acquires-invivodata-to-establish-the-industrys-most-experienced-provider-of-clinical-outcome-assessment-solutions-161777825.html [accessed 20.03.2026].

PR Newswire (2016). Cinven to Acquire Bioclinica. [online]. Available at: https://www.prnewswire.com/news-releases/cinven-to-acquire-bioclinica-300316540.html [accessed 25.03.2026].

Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (GDPR) [2016] OJ L119/1.

Reuters (2024). Clario files confidentially for US IPO, Bloomberg reports. [online]. Available at: https://finance.yahoo.com/news/clario-files-confidentially-us-ipo-193235531.html [accessed 20.03.2026].

Thermo Fisher Scientific (2024). 2024 Annual Report. [online]. Available at: https://ir.thermofisher.com/financial-information/annual-reports [accessed 20.03.2026].

Thermo Fisher Scientific (2025). Press Release: Thermo Fisher Scientific to Acquire Clario Holdings, Inc. [online]. Available at: https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Acquire-Clario-Holdings-Inc--Enabling-Pharma-and-Biotech-Customers-to-Accelerate-Innovation-with-Deeper-Clinical-Insights/default.aspx [accessed 24.03.2026].

Thermo Fisher Scientific (2026). Press Release: Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc. [online]. Available at: https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Completes-Acquisition-of-Clario-Holdings-Inc-/default.aspx [accessed 25.03.2026].

US Department of Justice and Federal Trade Commission (2023). Merger Guidelines. [online]. Available at: https://www.justice.gov/atr/2023-merger-guidelines [accessed 20.03.2026].

US Food and Drug Administration (2003). 21 CFR Part 11: Electronic Records; Electronic Signatures — Scope and Application. [online]. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application [accessed 20.03.2026].